Table 6. Rare EGFR and KRAS mutations and tumor response to EGFR TKI.

Mutations	N	Response	Response	Published response to
		to chemotherapy	to EGFR TKI	EGFR TKI
EGFR mutations
p.K708N	1	PD	PD (E)	[47]PR with
				gefitinib with
				p.K708M
p.V769M	1	PR	PD (E)	[33], [48];
				No treatment
				information
p. D770GY	1	PD	PR (E)	[36], [37]
with a secondary				No treatment
p.G719C mutation				information
p.D770GY;	1	PR	PD (G)	[36], [37]
without secondary				No treatment
mutation				information
p.L833F	1	PR	PD (G)	ND
(dual KRAS mutation)
p.A840T	2	PR/PR	PD (E)/–	ND
KRAS mutations
p.G13Y	1	PD	–	ND
p.V14L	1	PR	–	ND

PR is partial response, PD is progressive disease, –  =  no EGFR TKI treatment; (E) = erlotinib, (G) = gefitinib, ND = Not described.